• Home  
  • Capsida trial death is probed to keep promising gene therapy viable
Capsida trial death is probed to keep promising gene therapy viable
- Health

Capsida trial death is probed to keep promising gene therapy viable

Researchers on Friday presented detailed investigations into a gene therapy death that sparked fear and uncertainty last year among scientists who felt they had been approaching powerful treatments for a long list of brain diseases. The researchers did not conclude precisely what led to the patient’s death but proposed experiments to screen future therapies. “What

Researchers on Friday presented detailed investigations into a gene therapy death that sparked fear and uncertainty last year among scientists who felt they had been approaching powerful treatments for a long list of brain diseases.

The researchers did not conclude precisely what led to the patient’s death but proposed experiments to screen future therapies.

“What I want everyone to take home is: I think we’re starting to build a framework for testing this,” said Nicholas Flytzanis, chief research and innovation officer at Capsida Biotherapeutics. “I think it can be tested, and I think this specific novel risk is one that we can try to mitigate and predict in the future.”

STAT+ Exclusive Story





This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

Source: www.statnews.com

About Us

Toolq Media Is a Global News Platform Covering the Latest Developments and Breaking Stories from Around The World, Including World News, Business, Finance, Technology, Health, Politics, Science, Entertainment, Sports, and More.

Toolq

Toolq @2026. All Rights Reserved.